Compare Amphastar Pharmaceuticals Inc (AMPH) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs LyondellBasell Industries NV — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while LyondellBasell Industries NV trades at $63.87 (market cap $20.24B). The key difference: LyondellBasell Industries NV is far larger — about 23.4× Amphastar Pharmaceuticals Inc's market cap, and LyondellBasell Industries NV pays a 6.58% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LYB | |
|---|---|---|
Market Cap | $863.95M | $20.24B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $82.38 |
52-Week Low | $16.87 | $42.28 |
Enterprise Value | $1.26B | $31.83B |
Dividend Yield | — | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
LyondellBasell Industries (LYB) trades at $59.595, down 2.97% on the day, with a bearish technical signal. The company reported a strong Q2 2026 earnings beat ($4.30 EPS vs. $3.44 expected) but faces declining revenue and negative net income margins. Recent news highlights supply disruptions supporting margins, while analyst consensus is a Buy with a $70.56 price target, implying 18% upside.
Outlook is mixed: earnings momentum and undervaluation (P/S 0.62) offer opportunity, but weak profitability and high debt pose risks. The stock's direction hinges on margin sustainability and broader economic conditions affecting chemical demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
